Personalizing guidelines for diabetes management: twilight or dawn of the expert?
BMC Medicine 2013, 11:161 (10 July 2013)
This article is part of a collection on
Stavroula Paschou and David Leslie discuss the limitations of guidelines for managing type 2 diabetes and recommend that a more personalized approach is required, taking multiple targets and therapies into account.
Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial
BMC Medicine 2013, 11:160 (9 July 2013)
Trial shows promising results for patients with type 2 diabetes by using cord blood stem cells to re-educate mononuclear cells before returning them to the patient’s circulation, resulting in improved long term metabolic control.
Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study
BMC Medicine 2013, 11:46 (21 February 2013)
Gut microbiota are present at lower quantity and have different composition in children with type 1 diabetes compared with healthy children, possibly due to altered gut permeability, and modification of these bacteria could control diabetes development.
Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventive strategy
BMC Medicine 2013, 11:45 (21 February 2013)
The predictive ability of a screening tool for diabetes is reduced when the proposed new hemoglobin-based criteria are used for diagnosis instead of glucose, suggesting that glucose should be measured to assess diabetes risk using this score.
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
BMC Medicine 2013, 11:43 (20 February 2013)
In a 102 week trial, addition of dapagliflozin to metformin therapy for type 2 diabetes patients was effective for glycemic control in those who are inadequately controlled by metformin alone, suggesting a novel therapeutic option for those requiring long-term management.
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
BMC Medicine 2013, 11:1 (2 January 2013)
Evidence from a meta-analysis shows a plasminogen activator inhibitor-1 gene polymorphism increases diabetic retinopathy risk in Caucasians and in patients who have had diabetes for more than 10 years, but not in Chinese and Japanese patients.
Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
BMC Medicine 2012, 10:152 (30 November 2012)
Melanie Davies and colleagues review the differences between two incretin-based therapies for type 2 diabetes, glucagon-like peptide agonists and dipeptidyl peptidase 4 inhibitors, and recommend effective and safe individualized treatment.
Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis
BMC Medicine 2012, 10:119 (10 October 2012)
This article is part of a collection on
Metabolism, diet and...
A systematic review and meta-analysis finds increased body iron stores and higher heme iron intake are linked to a higher risk of type 2 diabetes, while non-heme iron intake is not, suggesting that caution needs to be applied in the type and amount of iron supplementation.
The impact of diabetes on tuberculosis treatment outcomes: A systematic review
BMC Medicine 2011, 9:81 (1 July 2011)
The growing epidemic of diabetes mellitus (DM) poses a threat for tuberculosis (TB) control as DM is associated with an increased risk of failure, death and relapse among people with TB, highlighting the need to jointly manage the diseases.
Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (riyadh cohort 2): a decade of an epidemic
BMC Medicine 2011, 9:76 (20 June 2011)
A decade-long epidemiological follow-up study on the prevalence of major chronic, non-communicable diseases in the Kingdom of Saudi Arabia finds an alarming rise in the prevalence of type 2 diabetes, hypertension and coronary artery disease.